Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.

doi:10.1016/j.mehy.2016.09.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.

Medical hypotheses - 1 Nov 2016

Das Samayita

Abstract excerpt

Triple negative breast cancer (TNBC) is a heterogeneous form of malignant disease. Due to lack of proper therapeutic target treatment options are restricted and relies primarily on chemotherapeutic modality for treatment of patients. Despite significant early regression of the disease in response to chemotherapy, complete cure is not assured with development of resistant tumors which is difficult to manage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Fibroblasts
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune System

Share to MicroRNAs

Share to Neoplasm Recurrence, Local

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 27959276
DOI: 10.1016/j.mehy.2016.09.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.